Thrivent Financial for Lutherans Has $24.50 Million Holdings in Pfizer Inc. (NYSE:PFE)

Thrivent Financial for Lutherans increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.5% during the third quarter, HoldingsChannel.com reports. The fund owned 846,582 shares of the biopharmaceutical company’s stock after purchasing an additional 107,346 shares during the period. Thrivent Financial for Lutherans’ holdings in Pfizer were worth $24,500,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. Claro Advisors LLC grew its holdings in Pfizer by 2.2% during the third quarter. Claro Advisors LLC now owns 41,762 shares of the biopharmaceutical company’s stock valued at $1,209,000 after purchasing an additional 879 shares during the last quarter. Ceera Investments LLC grew its stake in Pfizer by 13.2% in the 3rd quarter. Ceera Investments LLC now owns 52,051 shares of the biopharmaceutical company’s stock valued at $1,506,000 after buying an additional 6,065 shares during the last quarter. Chesapeake Capital Corp IL acquired a new position in Pfizer during the 3rd quarter worth $293,000. Gladius Capital Management LP boosted its holdings in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the period. Finally, Atlanta Consulting Group Advisors LLC increased its stake in shares of Pfizer by 274.5% in the third quarter. Atlanta Consulting Group Advisors LLC now owns 46,786 shares of the biopharmaceutical company’s stock worth $1,354,000 after purchasing an additional 34,293 shares during the period. 68.36% of the stock is owned by institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Price Performance

Shares of PFE stock opened at $25.10 on Wednesday. The stock’s fifty day simple moving average is $28.45 and its 200 day simple moving average is $28.63. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm has a market cap of $142.24 billion, a price-to-earnings ratio of 33.92, a P/E/G ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.17) EPS. On average, analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.69%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.